Table 3.
Comparison of the clinical characteristics of the splenectomized β-TM patients with β-TM patients (without splenectomized)
| Variables | Splenectomized β-TM (n = 7) | β-TM without splenectomized (n = 103) | p value |
|---|---|---|---|
| Age (years) | 12.0 (8.0–19.0)* | 10.0 (7.0–13.0)* | 0.298 |
| Hb (g/L) | 63.0 (55.0–75.0) | 65.0 (54.3–76.8) | 0.528 |
| Hct (%) | 20.4 (18.3–23.6) | 20.7 (18.0–24.4) | 0.420 |
| WBC × 109 (cells/L) | 9.65 (6.56–10.53) | 11.64 (7.78–30.39) | 0.338 |
| Platelet × 109 (cells/L) | 224.0 (207.0–297.0) | 287.0 (202.0–530.0) | 0.536 |
| TB (μmol/L) | 37.62 (15.39–51.30) | 34.20 (27.36–49.59) | 0.875 |
| DB (μmol/L) | 8.55 (5.13–10.26) | 6.84 (6.84–10.26) | 0.941 |
| AST (U/L) | 64.0 (54.0–98.0) | 65.0 (56.0–94.0) | 0.937 |
| ALT (U/L) | 84.0 (69.0–131.0) | 80.5 (69.0–107.3) | 0.981 |
| ALP (U/L) | 145.0 (127.0–187.0) | 130.0 (102.3–175.5) | 0.501 |
| TC (mmol/L) | 2.61 (2.24–3.12) | 2.97 (2.48–3.46) | 0.214 |
| TG (mmol/L) | 1.74 (1.51–1.88) | 1.66 (1.41–2.09) | 0.776 |
| LDL-C (mmol/L) | 1.37 (0.93–1.88) | 1.42 (1.17–1.89) | 0.508 |
| HDL-C (mmol/L) | 0.49 (0.39–0.80) | 0.66 (0.49–0.83) | 0.140 |
| VLDL-C (mmol/l) | 0.565 (0.511–0.669) | 0.545 (0.444–0.671) | 0.489 |
| Ferritin (μg/L) | 3,128.0 (658.0–4,909.0) | 2,610.2 (1,686.3–5,000.0) | 0.923 |
| MDA (μmol/L) | 7.68 (5.38–12.40) | 9.20 (6.63–15.69) | 0.329 |
| RC-MDA/g Hb (μmol/L) | 8.12 (7.20–9.46) | 7.55 (6.22–8.87) | 0.305 |
| TAC (mmol Trolox Equiv/L) | 0.510 (0.000–2.41) | 0.470 (0.000–0.510) | 0.432 |
P value <0.05, significant; * median (interquartile)
Hb hemoglobin, Hct hematocrit, TB total bilirubin, DB direct bilirubin, AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, TC total cholesterol, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol, MDA malondialdehyde, RC red blood cell, /g Hb per gram hemoglobin, TAC total antioxidant capacity